A Study of AZD0486 for B-Cell Non-Hodgkin Lymphoma
Phase 1
317
about 7.1 years
18–130
10 sites in FL, KY, NC +6
Why this study is shown
What this study is about
This trial is testing the safety and how well AZD0486 works in people with B-cell non-Hodgkin lymphoma. AZD0486 is a type of drug given through an IV infusion.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive AZD0486 IV
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Assignment is predetermined by the study protocol.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
infusion
Primary: Apparent terminal half-life (t1/2) of AZD0486, Incidence of subjects with Dose-limiting toxicities (DLT), Incidence of subjects with adverse events (AEs) and/or serious adverse events (SAEs), Maximum Observed Serum Concentration of AZD0486 (Cmax)
Secondary: Anti-Lymphoma Activity by Duration of Objective Response (DOR), Anti-Lymphoma Activity by Objective Response Rate (ORR), Anti-Lymphoma Activity by Progression-Free Survival (PFS)
Oncology